Status: Recruiting
Evaluation of Eflornithine Plus Temozolomide in Patients With Newly Diagnosed Glioblastoma or Astrocytoma
The purpose of this study is to establish the recommended phase 2 dose of eflornithine in combination with temozolomide in patients whose glioblastoma or astrocytoma is newly diagnosed, and to evaluate safety and tolerability of this combination at that dose.
Participants needed: 66
Trial details
Phase: Phase 1Age: 18+Biological sex: AllType: InterventionalSponsor: Orbus Therapeutics, Inc.Updated: Jun 25, 2025Locations: 8
Eligibility criteria
Diagnosis of World Health Organization (WHO) G4 classified GBM, IDH-wildtype (pa... [+5]
Recent history of recurrent or metastatic cancer that could confound response as... [+7]